Cosmos Health Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Cosmos Health şirketinin toplam hissedar öz sermayesi $35.0M ve toplam borcu $10.3M olup, bu da borç-öz sermaye oranını 29.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $64.5M ve $29.5M dir.

Anahtar bilgiler

29.4%

Borç/özkaynak oranı

US$10.29m

Borç

Faiz karşılama oranı	n/a
Nakit	US$3.34m
Eşitlik	US$34.98m
Toplam yükümlülükler	US$29.54m
Toplam varlıklar	US$64.52m

Son finansal sağlık güncellemeleri

Recent updates

Positive Sentiment Still Eludes Cosmos Health Inc. (NASDAQ:COSM) Following 26% Share Price Slump

Aug 16

Slammed 27% Cosmos Health Inc. (NASDAQ:COSM) Screens Well Here But There Might Be A Catch

Feb 23

Cosmos climbs 11% on Cana Laboratories acquisition, expanding product line and integrating vertically

Jul 20

Cosmos Holdings to acquire bone health product portfolio from LIFE NLB

Jul 06

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: COSM 'nin kısa vadeli varlıkları ( $36.2M ) kısa vadeli yükümlülüklerini ( $25.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: COSM şirketinin kısa vadeli varlıkları ( $36.2M ) uzun vadeli yükümlülüklerini ( $4.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: COSM 'nin net borç/öz sermaye oranı ( 19.9% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: COSM şirketinin 5 yıl önce negatif özkaynağı vardı, ancak şu anda pozitif ve dolayısıyla iyileşme kaydetti.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: COSM şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: COSM un, serbest nakit akışı her yıl % 27.7 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Cosmos Health Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Cosmos Health Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price

Cosmos Health Regains Full Compliance with Nasdaq Listing Requirements

Cosmos Health Inc. announced delayed 10-Q filing

Cosmos Health Receives Additional Delinquency Letter from Nasdaq Regarding Late Filings of its Forms 10-K and 10-Q

Cosmos Health Inc. announced delayed 10-Q filing

Cosmos Health Inc. announced delayed annual 10-K filing

Recent updates

New major risk - Shareholder dilution

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Cosmos Health Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price

Cosmos Health Inc., Annual General Meeting, Nov 19, 2024

Cosmos Health Inc. Provides Earnings Guidance for the Year 2024, 2025, 2026, 2027

Cosmos Health Regains Full Compliance with Nasdaq Listing Requirements

Positive Sentiment Still Eludes Cosmos Health Inc. (NASDAQ:COSM) Following 26% Share Price Slump

Cosmos Health Inc. announced delayed 10-Q filing

Cosmos Health Receives Additional Delinquency Letter from Nasdaq Regarding Late Filings of its Forms 10-K and 10-Q

Cosmos Health Inc. announced delayed 10-Q filing

Cosmos Health Inc. announced delayed annual 10-K filing

Cosmos Health Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price

Cosmos Health Inc. Commences Development of Cloudscreen 2.0 the New Iteration of Its Next Generation AI Drug Repurposing Platform

Cosmos Health Inc. Receives Regulatory Approval to Sell Sky Premium Life Products in UAE Nutritional Supplements Market

New major risk - Financial position

Cosmos Health Inc. has filed a Follow-on Equity Offering in the amount of $5.049535 million.

Slammed 27% Cosmos Health Inc. (NASDAQ:COSM) Screens Well Here But There Might Be A Catch

High number of new and inexperienced directors

Cosmos Health Inc. (NasdaqCM:COSM) completed the acquisition of Cloudscreen.

Cosmos Health Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

Cosmos Health Inc. (NasdaqCM:COSM) signed an agreement to acquire Cloudscreen.

Cosmos Health Inc. Announces Executive and Board Changes

Cosmos Health Inc. Provides Earnings Guidance for the Year 2023

Cosmos Health Inc., Annual General Meeting, Sep 18, 2023

Cosmos Health Inc. announced delayed 10-Q filing

Second quarter 2023 earnings released: US$0.091 loss per share (vs US$23.37 loss in 2Q 2022)

Cosmos Health Inc. announced that it has received $5.25 million in funding

Cosmos Holdings Inc. (NasdaqCM:COSM) acquired 100% stakes in Cana Laboratories S.A. for approximately $1.67 million.

Cosmos Health Inc. Launches Terra Creta

Cosmos Health Inc. entered into letter of intent agreement to acquire Docpharm Arzneimittelvertrieb Gmbh & Co. Kg Auf Aktien.

Cosmos Health Inc. announced delayed 10-Q filing

Full year 2022 earnings released: US$33.16 loss per share (vs US$23.74 loss in FY 2021)

Cosmos Health Inc. Appoints Nikos Bardakis as Chief Operating Officer

Cosmos Health Inc. (NasdaqCM:COSM) announces an Equity Buyback for $3 million worth of its shares.

Cosmos Health Inc. announced that it has received $32.52568 million in funding

Cosmos Health Inc. announced that it has received $32.52568 million in funding

Cosmos Health Inc. has completed a Follow-on Equity Offering in the amount of $32.52568 million.

Cosmos Health Inc. has completed a Follow-on Equity Offering in the amount of $32.52568 million.

Chairman & CEO exercised options to buy US$605k worth of stock.

Cosmos Health Enters the Development Phase for CCX0722, an Innovative Product for Obesity and Weight Management

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.11 loss in 3Q 2021)

Cosmos Holdings Inc., Annual General Meeting, Dec 02, 2022

Cosmos Holdings Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.

Cosmos Holdings Inc. (NasdaqCM:COSM) entered into a non-binding letter of intent agreement to acquire ZipDoctor, Inc from American International Holdings Corp. (OTCPK:AMIH).

Cosmos Holdings intends to acquire telemedicine platform ZipDoctor

Cosmos Holdings reports Q2 results

Cosmos Holdings Inc. announced delayed 10-Q filing

Cosmos Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price

Cosmos changes name to Cosmos Healthto

Cosmos Holdings Inc. (NasdaqCM:COSM) entered into a binding letter of intent to acquire Cana Laboratories S.A.

Cosmos climbs 11% on Cana Laboratories acquisition, expanding product line and integrating vertically

Cosmos Holdings, Inc. Appoints Dr. Panagiotis Zoumpoulakis to its Advisory Board

Cosmos Holdings Inc. (NasdaqCM:COSM) entered into an agreement to acquire product portfolio of Life NLB, Ltd.

Cosmos Holdings to acquire bone health product portfolio from LIFE NLB

Cosmos Holdings Inc. announced delayed 10-Q filing

Cosmos Holdings Inc. announced delayed annual 10-K filing

Cosmos Holdings Inc. announced delayed annual 10-K filing

Cosmos Holdings, Inc. Launches Osteodome in EU

Cosmos Holdings Inc. Launches New Proprietary Enhanced Dietary Supplement

Cosmos Holdings Inc. Appoints Georgios Terzis as Chief Financial Officer

Cosmos Holdings Inc. Announces David Lowenstein Agrees to Join Cosmos Board of Directors

Cosmos Holdings Inc. Announces Executive Changes

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin